Author Response for "the Efficacy and Safety of Insulin Pump Therapy with Predictive Low Glucose Suspend Feature in Decreasing Hypoglycemia in Children with Type 1 Diabetes Mellitus: a Systematic Review and Meta‐analysis"

Pediatric DiabetesVolume 21, Issue 7 p. 1256-1267 CLINICAL CARE AND TECHNOLOGY The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis Ahlam Alotaibi, Ahlam Alotaibi orcid.org/0000-0001-7419-2453 Department of Pediatrics, Division of Pediatric Endocrinology, King Abdullah bin Abdulaziz University Hospital, Princess Noura University, Riyadh, Saudi ArabiaSearch for more papers by this authorReem Al Khalifah, Corresponding Author Reem Al Khalifah ralkhalifah@ksu.edu.sa orcid.org/0000-0002-5304-3528 Division of Pediatric Endocrinology, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia Correspondence Reem Al Khalifah, Division of Pediatric Endocrinology, Department of Pediatrics, College of Medicine, King Saud University, P.O Box 2925, Riyadh 11461, Saudi Arabia. Email: ralkhalifah@ksu.edu.saSearch for more papers by this authorKaren McAssey, Karen McAssey Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this author Ahlam Alotaibi, Ahlam Alotaibi orcid.org/0000-0001-7419-2453 Department of Pediatrics, Division of Pediatric Endocrinology, King Abdullah bin Abdulaziz University Hospital, Princess Noura University, Riyadh, Saudi ArabiaSearch for more papers by this authorReem Al Khalifah, Corresponding Author Reem Al Khalifah ralkhalifah@ksu.edu.sa orcid.org/0000-0002-5304-3528 Division of Pediatric Endocrinology, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia Correspondence Reem Al Khalifah, Division of Pediatric Endocrinology, Department of Pediatrics, College of Medicine, King Saud University, P.O Box 2925, Riyadh 11461, Saudi Arabia. Email: ralkhalifah@ksu.edu.saSearch for more papers by this authorKaren McAssey, Karen McAssey Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this author First published: 01 August 2020 https://doi.org/10.1111/pedi.13088Citations: 10Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Background Automated insulin delivery with predictive low glucose suspend (PLGS) feature has the potential to reduce risk of hypoglycemia in patients with type 1 diabetes mellitus (T1DM). We aim to systematically synthesize the evidence on the efficacy and safety of PLGS in children and adolescents with T1DM. Methods We performed a systematic search through Ovid/MEDLINE, Ovid/Embase, and other search engines. We included randomized controlled trials (RCTs) evaluating the effect of sensor augmented pump (SAP) with PLGS feature compared to SAP or insulin pump therapy without SAP in decreasing hypoglycemia in children and adolescents aged 2 to 18 years with T1DM, with at least 2 weeks of follow-up. Two reviewers independently selected studies, extracted data, and evaluated the risk of bias (ROB). Results Five RCTs with total sample size of 493 children aged 6 to 18 years met the inclusion criteria. The overall ROB of included studies was low. There is high quality evidence that PLGS is superior to SAP in decreasing time spent in hypoglycemia (sensor glucose [SG] <3.9 mmol/L [<70 mg/dL]/24 h) and nocturnal hypoglycemia (SG <3.9 mmol [<70 mg/dL]/L/night) with an absolute mean difference of 17.4 min/d (95% CI: −19.2, –15.5) and 26.3 min/night (95% CI: −35.5, −16.7), respectively, without increasing percentage of time spent in hyperglycemia or episodes of diabetic ketoacidosis (DKA). There was insufficient evidence for the impact of PLGS on health related quality of life (HRQL). Conclusions PLGS is superior to SAP in decreasing daytime and nocturnal hypoglycemia without increasing the risk of DKA or hyperglycemia. Future studies should address the impact of PLGS on children younger than 6-years-old and HRQL. Open Research PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1111/pedi.13088. Citing Literature Supporting Information Filename Description pedi13088-sup-0001-Supinfo.docxWord 2007 document , 799.5 KB Data S1: Supporting information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume21, Issue7November 2020Pages 1256-1267 RelatedInformation